Source link : https://www.newshealth.biz/health-news/pirtobrutinib-delays-progression-in-cll-already-treated-with-a-btk-inhibitor/
SAN DIEGO — Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton’s tyrosine kinase (BTK) inhibitor, a phase III study showed. Median progression-free survival (PFS) reached 14 months with pirtobrutinib, an oral non-covalent BTK inhibitor, as compared with 8.7 months with […]
Author : News Health
Publish date : 2024-12-11 15:44:29
Copyright for syndicated content belongs to the linked Source.